Neutropenia and Neutropenic Complications in ABVD Chemotherapy for Hodgkin Lymphoma | Zendy

Bhanu K Vakkalanka | Zendy; Brian K. Link | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Neutropenia and Neutropenic Complications in ABVD Chemotherapy for Hodgkin Lymphoma

Author(s) -

Bhanu K Vakkalanka,

Brian K. Link

Publication year - 2011

Publication title -

advances in hematology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.371

H-Index - 31

eISSN - 1687-9112

pISSN - 1687-9104

DOI - 10.1155/2011/656013

Subject(s) - abvd , medicine , dacarbazine , neutropenia , vinblastine , hodgkin lymphoma , bleomycin , chemotherapy , lymphoma , doxorubicin , oncology , intensive care medicine , hodgkin's lymphoma , surgery , vincristine , cyclophosphamide

A combination of Adriamycin (a.k.a. Doxorubicin), Bleomycin, Vinblastine, and Dacarbazine (ABVD) is the most commonly used chemotherapy regime for Hodgkin lymphoma. This highly effective treatment is associated with a significant risk of neutropenia. Various strategies are adopted to counter this commonly encountered problem, including dose modification, use of colony stimulating factors, and prophylactic or therapeutic use of antibiotics. Data to support these approaches is somewhat controversial, and in keeping with the paucity of definitive evidence, there is a wide disparity in the management of neutropenia in patients receiving ABVD chemotherapy. This paper summarizes the evidence for managing ABVD-related neutropenia during the treatment of Hodgkin lymphoma.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research